Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
Crossref DOI link: https://doi.org/10.1007/s00259-017-3648-x
Published Online: 2017-02-24
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Basu, Sandip
Kalshetty, Ashwini
License valid from 2017-02-24
